Leerink Swann Reaffirms “Buy” Rating for GW Pharmaceuticals PLC- (GWPH)

GW Pharmaceuticals PLC- (NASDAQ:GWPH)‘s stock had its “buy” rating reaffirmed by investment analysts at Leerink Swann in a report released on Tuesday. They presently have a $153.00 price objective on the biopharmaceutical company’s stock. Leerink Swann’s target price would indicate a potential upside of 11.11% from the company’s current price.

Other research analysts have also issued research reports about the company. BidaskClub upgraded GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. Goldman Sachs Group upgraded GW Pharmaceuticals PLC- from a “neutral” rating to a “buy” rating and set a $174.00 target price on the stock in a report on Thursday, December 14th. Cantor Fitzgerald set a $208.00 target price on GW Pharmaceuticals PLC- and gave the company a “buy” rating in a report on Monday, December 4th. Bank of America dropped their target price on GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating on the stock in a report on Tuesday, November 14th. Finally, Zacks Investment Research upgraded GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. GW Pharmaceuticals PLC- has a consensus rating of “Hold” and an average price target of $148.78.

GW Pharmaceuticals PLC- (NASDAQ GWPH) traded up $3.95 during mid-day trading on Tuesday, hitting $137.70. The stock had a trading volume of 539,588 shares, compared to its average volume of 411,307. GW Pharmaceuticals PLC- has a 52 week low of $92.65 and a 52 week high of $140.52. The company has a quick ratio of 7.47, a current ratio of 7.59 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $3,490.00, a price-to-earnings ratio of -18.91 and a beta of 2.65.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its earnings results on Monday, December 4th. The biopharmaceutical company reported ($2.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.73) by ($0.45). GW Pharmaceuticals PLC- had a negative net margin of 1,607.85% and a negative return on equity of 40.42%. research analysts expect that GW Pharmaceuticals PLC- will post -7.83 EPS for the current year.

Institutional investors have recently modified their holdings of the stock. IHT Wealth Management LLC lifted its holdings in GW Pharmaceuticals PLC- by 18.0% during the second quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 100 shares during the period. Advisor Group Inc. lifted its holdings in GW Pharmaceuticals PLC- by 10.7% during the second quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 145 shares during the period. BNP Paribas Arbitrage SA bought a new stake in GW Pharmaceuticals PLC- during the second quarter worth $163,000. Van Hulzen Asset Management LLC bought a new stake in GW Pharmaceuticals PLC- during the third quarter worth $205,000. Finally, Ameriprise Financial Inc. lifted its holdings in GW Pharmaceuticals PLC- by 8.5% during the second quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 162 shares during the period. Institutional investors and hedge funds own 74.55% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Leerink Swann Reaffirms “Buy” Rating for GW Pharmaceuticals PLC- (GWPH)” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/23/leerink-swann-reaffirms-buy-rating-for-gw-pharmaceuticals-plc-gwph.html.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply